Despite losing patent protection for the world's bestselling drug next year, Pfizer (NYSE: PFE) R&D chief Martin Mackay says the company will be sitting pretty for years to come, thanks to its pipeline and the acquisition of Wyeth last year. "We're in the golden age of drug discovery," Mackay says. Report